How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Life Bio: epigenetic rejuvenation ‘transcends organs’
Longevity biotech presents data demonstrating therapeutic impact of partial epigenetic reprogramming across multiple biological systems. Today at the…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…